


Infobox drug

<! Clinical data >

<! Legal status >

<! Pharmacokinetic data >

<! Identifiers >

<! Chemical and physical data >


Bexagliflozin sold under the brand name Brenzavvy is an antidiabetic medication used to improve glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise It is a SGLT2 inhibitor
 Medical uses 
Bexagliflozin is indicated to improve glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise

 Research 
A 96week phase 2 clinical study of adults with type 2 diabetes showed that bexagliflozin monotherapy provided a durable clinically meaningful improvement of glycemic control with a substantial reduction in weight and blood pressure but no increase in the rate of significant adverse events In a clinical study of patients with type 2 diabetes and stage 3a/3b chronic kidney disease bexagliflozin was well tolerated and shown to reduce hemoglobin A1c levels body weight systolic blood pressure and albuminuria

 Veterinary uses 
The data from two sixmonth field studies and an extended use field study demonstrated that bexagliflozin was over 80% effective in improving glycemic control in cats with diabetes mellitus

Bexagliflozin sold under the brand name Bexacat is an antidiabetic medication used to improve glycemic control in cats with diabetes It was approved for medical use in the United States in December 2022 Bexacat is sponsored by Increvet Inc based in Boston Massachusetts Elanco licensed development and commercialization rights for bexagliflozin from Bexcafe an affiliate of Increvet

 References 


 Further reading 
 
 

 External links 
 







